Sambrinvest

Sambrinvest S.A. is a private equity and venture capital firm located in Gosselies, Belgium, founded in 1985. The firm specializes in both direct and fund of funds investments, focusing primarily on startup, spin-out, spin-off, growth capital, and turnaround opportunities. Sambrinvest avoids investments in the retail, hospitality, and banking and insurance sectors, while actively seeking opportunities in a wide range of industries including Agri-Food, audiovisual, gaming, automotive, biotechnology, pharmaceuticals, construction, digital services, environmental and alternative energy, manufacturing, and logistics, among others. The firm primarily targets small and medium-sized companies in the Charleroi Sud-Hainaut and Thuin districts, investing up to €1.25 million in businesses with a turnover below €50 million. Investments may be made through various financial instruments, including minority stakes, subordinated loans, and unsecured loans.

Fabrice Carosella

Investment Manager

Géraldine Crosset

Investment Manager - Life Sciences

Xavier Daive

COO and Head of Unit

Grégoire Dupuis

CEO

Gilles Groignet

Investment Manager

Elisabeth de Halleux

Investment Manager - Life Sciences

Soon Lambert

Investment Manager

Yasmine Preyat

Investment Manager

Zoubir Sefsaf

CFO

Micheline Streel

Investment Manager

25 past transactions

Aerospacelab

Series B in 2022
Aerospacelab SA, founded in 2017 and headquartered in Mont-Saint-Guibert, Belgium, specializes in the development and manufacturing of satellites equipped with advanced sensors. The company focuses on addressing complex challenges in the aerospace sector by employing innovative approaches. In addition to satellite technology, Aerospacelab also creates tools that leverage artificial intelligence and machine learning to automate various tasks, enhancing operational efficiency and capabilities in space exploration and data collection.

Cake App

Seed Round in 2022
Cake App mission is to become the leading software technology provider that analyzes financial data to help people better understand, control and improve their finances, supported by a business model that shares our revenue with users.

HeartKinetics

Convertible Note in 2021
HeartKinetics is focused on developing innovative healthcare solutions for heart failure management. The company has created a smart wireless device that measures cardiac contractility alongside traditional electrocardiogram data. Their platform leverages cloud computing and artificial intelligence to analyze this data, delivering predictive insights that enhance treatment efficacy. By providing healthcare professionals with tailored feedback based on individual patient needs, HeartKinetics aims to enable more personalized and effective treatment strategies for heart failure patients.

PDC*line Pharma

Series B in 2021
PDC*line Pharma is a clinical-stage biotech company based in France and Belgium, focused on developing innovative active immunotherapies for cancer. The company specializes in a proprietary allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line), which are loaded with cancer-specific antigens to stimulate a robust immune response. Founded in April 2014 in Grenoble by Laurent Levy and Joel Plumas, the company emerged from a research program at the French Blood Bank that developed the PDC line from a patient with PDC leukemia. PDC*line Pharma aims to enhance cancer treatment efficacy by producing potent and scalable PDC lines that can boost antitumor responses, including the activation of neoantigens and specific cytotoxic T-cells, offering a more effective alternative to conventional vaccines.

HireRing

Seed Round in 2021
HireRing is the on-demand staffing platform connecting employers with top professional recruiters per vacancy request, and for the hiring fee they set upfront. Their platform makes it fast and easy for employers to submit their hiring needs to the adequate recruitment agencies, and for agencies to choose the adequate business opportunities to work on.

Sortlist

Series B in 2021
Because finding the right partner in the fast-growing digital environment is a hard task, we have built an online multi-criteria searching tool strongly linked to professional networks and peer-to-peer recommendations. Sortlist helps marketing managers find their partners in minutes and let them focus on building communication and marketing success. Start your search now on www.sortlist.com

Amyl Therapeutics

Series A in 2021
Amyl Therapeutics is a preclinical stage biotechnology company focused on developing therapeutics for various forms of amyloidosis. The company utilizes a novel mechanism to bind to the amyloid folds of toxic protein aggregates, including antibody light chain (AL) and transthyretin (TTR) aggregates, which contribute to systemic amyloidosis. Additionally, Amyl Therapeutics targets amyloid-β (Aβ), Tau, and α-synuclein aggregates associated with neurodegenerative diseases such as Alzheimer's and Parkinson's. By addressing multiple misfolded proteins responsible for both peripheral and central nervous system pathologies, the company aims to provide effective therapies that can prevent the accumulation of harmful protein aggregates in organs and the brain, offering new treatment options for patients suffering from these debilitating conditions.

Shyfter

Seed Round in 2021
Shyfter is a web and app-based platform that simplifies staff scheduling management for companies. Its application software enables employers to manage online schedules, service sheets, time tracking, and contracts efficiently. The platform facilitates seamless communication between employers and employees, addressing various administrative and legal challenges associated with staff scheduling. By offering customizable scheduling solutions, Shyfter allows organizations to create schedules tailored to their specific needs, preferences, and operational practices, thereby enhancing overall workforce management.

ExeVir

Series A in 2020
ExeVir Bio BV is a Belgium-based biotechnology company established in 2020, focused on developing single-domain antibody therapies to combat viral infections. The company utilizes a llama-derived antibody technology platform, specifically the VHH technology, to create robust antiviral treatments that offer broad protection against coronaviruses, including SARS-CoV-2. ExeVir's lead candidate, VHH72-FC, targets a conserved region on the virus's spike protein essential for cellular entry. This innovative approach not only aims to provide effective treatment and prevention strategies for viral infections but also enables rapid development of drug candidates in response to emerging health threats, ensuring stability and cost-effectiveness for global access. ExeVir Bio's therapies are designed to reduce viral load and inflammation, thereby supporting immune responses and protecting vulnerable populations, including healthcare workers and individuals with co-morbidities.

OncoDNA

Series B in 2020
OncoDNA SA is a Belgium-based company specializing in precision medicine for cancer treatment and genetic diseases. Founded in 2012, it leverages over 60 years of expertise in medical diagnostics, particularly in DNA sequencing and oncology analyses. The company offers a range of solutions, including OncoDEEP, a comprehensive theranostics tool for solid tumors that integrates DNA, RNA, and protein analysis to assist oncologists in making informed treatment decisions. Additionally, OncoDEEP&TRACE allows for the profiling of both solid and liquid biopsies, while OncoTRACE provides a personalized, non-invasive blood test for monitoring tumor progression and treatment efficacy. OncoSHARE facilitates collaboration among patients, oncologists, and the oncology community by streamlining sample management and data sharing. OncoDNA distributes its products both locally in Belgium and globally, supporting clinical guidance and research in oncology and genetic disorders.

Utopix

Seed Round in 2019
Utopix Pictures SA is a media creation platform based in Mont-Saint-Guibert, Belgium, founded in 2015. The company specializes in connecting clients with professionals in the photography, film, and image industries. Utopix aims to simplify the process of finding the right photographer or videographer for various business projects, offering a seamless way to transform ideas into visual content. By leveraging a network of local service providers across Europe, Utopix allows companies to manage their shooting needs efficiently, reducing costs and streamlining logistics. The platform serves as a comprehensive solution for organizations seeking quality visual content while ensuring a quick and effective hiring process.

Cognivia

Series B in 2019
Cognivia is a company specializing in the development of analytical tools aimed at enhancing the clinical development of new medicines. Founded in 2013 and headquartered in Gosselies, Belgium, Cognivia focuses on optimizing therapeutic drug development programs. Its flagship product, Placebell, improves test sensitivity by characterizing and managing the individual placebo response in various disease states, where this response can obscure the efficacy of important therapies. The company employs an academic approach to commercialize its technology, drawing on the extensive expertise of its founders and a professional network of advisors. Cognivia’s mission is to improve patient quality of life by assisting healthcare providers and pharmaceutical companies in identifying the most effective therapies for individual patients, while actively involving patients as critical stakeholders in the development process.

Smartbeam

Seed Round in 2019
Smartbeam is a construction-tech startup focused on enhancing collaboration and financial oversight in construction projects. The company is developing a budget management application that facilitates cooperation among various stakeholders, including general contractors, subcontractors, architects, and developers, from the tendering phase through project completion. By leveraging technology, Smartbeam aims to improve project efficiency and streamline workflows, thereby reducing rework and financial risks. The team comprises experts in construction, business, and software engineering, who are collaborating with experienced construction partners to co-develop the software. This initiative seeks to modernize and optimize construction budget management, ultimately promoting better productivity and reliability in financial planning for construction professionals.

Commuty

Seed Round in 2019
Commuty is a Belgium-based company that specializes in developing web and mobile applications for parking and mobility management. Founded in 2014, Commuty offers a smart parking management platform that organizes parking spot allocations and bookings in accordance with company policies, thereby enhancing flexibility and efficiency. The application also promotes alternative transportation methods, including carpooling and cycling, by connecting users with similar routes, managing shared bicycle usage, and automating kilometer refunds. Through these services, Commuty aims to facilitate mobility changes for employers and employees alike, ultimately leading to cost savings and reduced logistical constraints.

Sortlist

Series A in 2019
Because finding the right partner in the fast-growing digital environment is a hard task, we have built an online multi-criteria searching tool strongly linked to professional networks and peer-to-peer recommendations. Sortlist helps marketing managers find their partners in minutes and let them focus on building communication and marketing success. Start your search now on www.sortlist.com

Minoryx

Series B in 2018
Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

ChromaCure

Venture Round in 2018
ChromaCure will launch a drug development program to identify potential new candidates that selectively and potently inhibit cancer targets and potentially provide novel therapy for multiple forms of cancer, either as monotherapy or in combination with immunotherapy or chemotherapy.

Ncardia

Series B in 2017
Ncardia BV is a biotechnology company based in Leiden, the Netherlands, that specializes in developing and manufacturing human induced pluripotent stem cell-based solutions for drug discovery and cell therapy. Established in 2017, the company focuses on expediting the drug discovery and development process by utilizing high-quality iPSC technology. Ncardia's offerings include disease modeling, assay development, large-scale iPSC manufacturing, and iPSC-based screening. These capabilities enable researchers to conduct predictive human cellular assays for safety and efficacy testing of drug candidates, specifically enhancing cardiovascular and neural drug screening. Through its innovative approaches, Ncardia aims to provide valuable insights into human disease biology, thereby accelerating the overall drug discovery process.

Ncardia

Venture Round in 2017
Ncardia BV is a biotechnology company based in Leiden, the Netherlands, that specializes in developing and manufacturing human induced pluripotent stem cell-based solutions for drug discovery and cell therapy. Established in 2017, the company focuses on expediting the drug discovery and development process by utilizing high-quality iPSC technology. Ncardia's offerings include disease modeling, assay development, large-scale iPSC manufacturing, and iPSC-based screening. These capabilities enable researchers to conduct predictive human cellular assays for safety and efficacy testing of drug candidates, specifically enhancing cardiovascular and neural drug screening. Through its innovative approaches, Ncardia aims to provide valuable insights into human disease biology, thereby accelerating the overall drug discovery process.

Opinum

Series A in 2016
Opinum, headquartered in Braine l'Alleud, Belgium, specializes in developing digital web-based software that focuses on energy and environmental data management. The company's flagship product, the Opinum Data Hub, supports energy and environmental stakeholders in their digital transformation by facilitating all stages of the data management value chain. This platform allows users, primarily large private and public service companies, energy suppliers, and energy management experts, to analyze and visualize data related to asset consumption, including gas, water, and electricity. By enabling businesses to track and regulate their energy usage, Opinum empowers them to focus on their core competencies while effectively managing their energy consumption.

X4C

Seed Round in 2016
X4C specializes in the development and application of monolayer chemical coating technology. This innovative approach enables the creation of thin, uniform coatings that enhance the properties of various substrates. The technology is designed to improve performance and durability in a range of industries, providing solutions that address specific material challenges. By focusing on the unique advantages of monolayer coatings, X4C aims to deliver significant improvements in functionality while maintaining cost-effectiveness for its clients.

Opinum

Series A in 2016
Opinum, headquartered in Braine l'Alleud, Belgium, specializes in developing digital web-based software that focuses on energy and environmental data management. The company's flagship product, the Opinum Data Hub, supports energy and environmental stakeholders in their digital transformation by facilitating all stages of the data management value chain. This platform allows users, primarily large private and public service companies, energy suppliers, and energy management experts, to analyze and visualize data related to asset consumption, including gas, water, and electricity. By enabling businesses to track and regulate their energy usage, Opinum empowers them to focus on their core competencies while effectively managing their energy consumption.

Opinum

Seed Round in 2015
Opinum, headquartered in Braine l'Alleud, Belgium, specializes in developing digital web-based software that focuses on energy and environmental data management. The company's flagship product, the Opinum Data Hub, supports energy and environmental stakeholders in their digital transformation by facilitating all stages of the data management value chain. This platform allows users, primarily large private and public service companies, energy suppliers, and energy management experts, to analyze and visualize data related to asset consumption, including gas, water, and electricity. By enabling businesses to track and regulate their energy usage, Opinum empowers them to focus on their core competencies while effectively managing their energy consumption.

Calyos

Venture Round in 2012
Calyos SA specializes in the development, manufacturing, and commercialization of two-phase thermal management and cooling systems. The company offers its products for high power semiconductors, such as IGBT power modules and electronic components; and electrical engines cooling and energy storage applications. Calyos SA was founded in 2011 and is based in Jumet, Belgium.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.